Nixing the DOW-DD merger will lessen the impetus for regulators to block the Bayer-MON merger based on the argument that there are simply too few large players in the ag-tech industry.
As noted in my prior post, Bayer and MON have little overlap in their actual business lines.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.